We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+31.58%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$250M
AUM Growth
+$80.2M
Cap. Flow
+$54.1M
Cap. Flow %
21.67%
Top 10 Hldgs %
36.89%
Holding
128
New
62
Increased
6
Reduced
21
Closed
36

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$6.46M
2
HOLX
Hologic
HOLX
+$3.37M
3
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$2.9M
4
STAA icon
STAAR Surgical
STAA
+$2.34M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.33M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$4.14M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$4.09M
3
ABT icon
Abbott
ABT
+$3.63M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.54M
5
GMED icon
Globus Medical
GMED
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 37.06%
2 Industrials 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EOLS icon
101
Evolus
EOLS
$500M
– –
-102,544
Closed -$926K
EW icon
102
Edwards Lifesciences
EW
$53B
– –
-75,000
Closed -$3.49M
EXEL icon
103
Exelixis
EXEL
$13.1B
– –
-40,000
Closed -$886K
FATE icon
104
Fate Therapeutics
FATE
$322M
– –
-59,600
Closed -$582K
FOLD
105
DELISTED
Amicus Therapeutics
FOLD
– –
-100,000
Closed -$1.51M
INCY icon
106
Incyte
INCY
$24.6B
– –
-15,000
Closed -$1.03M
INCY icon
107
PUT
Incyte
INCY
$24.6B
– –
-50,000
Closed -$4.17M
KALA icon
108
KALA BIO
KALA
$14.6M
– –
-26
Closed -$1.03M
KALA icon
109
PUT
KALA BIO
KALA
$14.6M
– –
-6
Closed -$237K
MRK icon
110
CALL
Merck
MRK
$323B
– –
-209,600
Closed -$10.9M
QGEN icon
111
Qiagen
QGEN
$9.05B
– –
-70,729
Closed -$2.6M
RIGL icon
112
PUT
Rigel Pharmaceuticals
RIGL
$778M
– –
-60,000
Closed -$2.12M
UTHR icon
113
United Therapeutics
UTHR
$22.7B
– –
-20,000
Closed -$2.25M
NTBL
114
PUT
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-2,857
Closed -$230K
ACER
115
DELISTED
Acer Therapeutics Inc
ACER
– –
-41,795
Closed -$805K
JNCE
116
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-21,700
Closed -$485K
CSII
117
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-67,000
Closed -$1.84M
CFMS
118
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-29,242
Closed -$1.06M
NTUS
119
DELISTED
Natus Medical Inc
NTUS
– –
-57,620
Closed -$1.94M
ARNA
120
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-50,000
Closed -$1.98M
ALXN
121
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-30,000
Closed -$3.34M
GWPH
122
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-5,000
Closed -$710K
AIMT
123
DELISTED
Aimmune Therapeutics
AIMT
– –
-25,782
Closed -$821K
AGN
124
PUT
DELISTED
Allergan plc
AGN
– –
-10,000
Closed -$1.68M
ARRY
125
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-50,000
Closed -$816K
2 3 4
5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2018 Portfolio in Review

As of Q2 2018, Pura Vida Investments held 128 positions worth $250M, up 47% from $169M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $54.1M of net new capital in Q2 2018, opening 62 new positions and adding to 6 existing holdings. Its largest new stake was Inspire Medical Systems: 200,280 shares worth $7.14M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 52% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Merck, an estimated $4.14M trimmed.

  • Pura Vida Investments's largest Q2 2018 buy was Inspire Medical Systems: 200,280 shares worth $7.14M.
  • Pura Vida Investments added most to Allergan plc in Q2 2018, an estimated $1.61M increase.
  • Pura Vida Investments's biggest Q2 2018 reduction was Merck, cutting an estimated $4.14M.
  • Pura Vida Investments fully exited Abbott in Q2 2018, selling an estimated $3.63M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $250M portfolio in Q2 2018.
  • Pura Vida Investments opened 62 new positions and closed 36 in Q2 2018.
  • Pura Vida Investments's portfolio value rose 47% quarter-over-quarter to $250M.

Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.